Israel vs Laos: The number of people with susceptibility test result for rifampicin
Israel
100
in 2021
Laos
100
in 2021
Israel rank
2nd
Laos rank
2nd
The number of people with susceptibility test result for rifampicin over time
- Israel
- Laos
How they compare
Israel currently reports 100 against 100 in Laos, a difference of 0.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Israel ahead.
Israel ranks 2nd and Laos ranks 2nd of 146 countries.
Israel has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Israel | Laos | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 98.2 | 64.84 | 33.36 | Israel |
| 2020s | 100 | 94.5 | 5.5 | Israel |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Israel or Laos?
- Israel, at 100 against 100 in Laos as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Israel and Laos?
- 0, with Israel ahead.
- How many years of comparable data are there for Israel and Laos?
- 5 years are reported by both, from 2017 to 2021.
- How do Israel and Laos rank globally for the number of people with susceptibility test result for rifampicin?
- Israel ranks 2nd and Laos ranks 2nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.